Search

Search Constraints

You searched for: Author/Creator Bacac, Marina

Search Results

1. Antitumour activity of the glycoengineered type II anti‐CD20 antibody obinutuzumab (GA101) in combination with the MDM2‐selective antagonist idasanutlin (RG7388). (18th April 2016)

2. Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB. Issue 7 (September 2016)

4. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. (4th March 2017)

6. Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-derived dendritic cells. Issue 6 (10th June 2022)

7. Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils. (31st December 2022)

8. Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor. (1st February 2016)

9. Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor. (1st February 2016)

10. Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer. Issue 2 (2nd July 2020)